Suppr超能文献

肝移植术后肝动脉血栓的血管内治疗。

Endovascular treatment of hepatic artery thrombosis following liver transplantation.

机构信息

Nazih Zuhdi Transplant Institute, INTEGRIS Baptist Medical Center, Oklahoma City, OK 73112, USA.

出版信息

Transpl Int. 2010 Mar 1;23(3):245-56. doi: 10.1111/j.1432-2277.2009.01037.x. Epub 2009 Dec 22.

Abstract

Hepatic artery thrombosis (HAT) is the most frequent vascular complication following orthotopic liver transplantation. Urgent retransplantation has been considered as the mainstay therapy. Surgical revascularization is an effective alternative in asymptomatic patients. Endovascular therapies including intra-arterial thrombolysis, percutaneous transluminal angioplasty (PTA), and stent placement have shown encouraging results in recent years; however, their use remains controversial because of potential risk of hemorrhage. Until June 2009, 69 cases were published in 16 reports describing therapeutic potential of endovascular modalities. Interventions were performed as early as within 4 h to as late as 120 days in patients ranging from 4 months to 64 years of age. Majority of published reports suggested the use of urokinase. Thrombolysis was successful in 47 out of 69 (68%) patients. Bleeding was the most common complication including fatal intra-abdominal hemorrhage in three patients. Twenty-nine out of 47 (62%) patients underwent further intervention in the form of PTA, stenting, or both. The follow-up patency ranged from 1 month to 26 months. In conclusion, whenever possible, efforts should be made to rescue the liver grafts through urgent revascularization (surgical and/or endovascular) depending on patient's condition and interventional expertise at the transplant center; reserving the option of retransplantation for failure, complications, and cases with severe clinical symptoms or allograft dysfunction.

摘要

肝动脉血栓形成(HAT)是肝移植后最常见的血管并发症。紧急再次移植被认为是主要的治疗方法。在无症状患者中,手术血运重建是一种有效的替代方法。近年来,包括动脉内溶栓、经皮腔内血管成形术(PTA)和支架置入在内的血管内治疗方法已显示出令人鼓舞的结果;然而,由于潜在的出血风险,其应用仍存在争议。截至 2009 年 6 月,在 16 份报告中描述了 69 例经血管内方式治疗的潜在疗效。在年龄 4 个月至 64 岁的患者中,干预时间最早为发病后 4 小时,最晚为 120 天。大多数已发表的报告都建议使用尿激酶。在 69 例患者中,47 例(68%)溶栓成功。出血是最常见的并发症,包括 3 例致命性腹腔内出血。在 47 例溶栓成功的患者中,29 例(62%)进一步接受了 PTA、支架置入或两者联合的治疗。随访通畅时间从 1 个月到 26 个月不等。总之,应根据患者的情况和移植中心的介入专业知识,通过紧急血运重建(手术和/或血管内)努力挽救移植肝,保留再次移植的选择,以防失败、并发症和有严重临床症状或移植物功能障碍的病例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验